| Field | Specification |
|---|---|
| Alternative names | Indometacin farnesil |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C34H40ClNO4 |
| Purity | |
| SMILES | |
| Form | Oil |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Indomethacin farnesil is an orally active prodrug of indomethacin. Once converted, it acts as a potent, blood-brain-permeable, nonselective inhibitor of COX-1 and COX-2, with IC50 values of 18 nM and 26 nM against human COX-1 and COX-2, respectively, in CHO cells, and disrupts autophagic flux by impairing normal lysosomal function[1][2]. It is supplied as a light yellow to yellow oil (C34H40ClNO4, MW 562.14) at 97.29% purity.
Physical & Chemical Properties
| CAS Number | 85801-02-1 |
|---|---|
| Molecular Formula | C34H40ClNO4 |
| Molecular Weight | 562.14 g/mol |
| Purity | 97.29% |
| Appearance | Oil |
| Color | Light yellow to yellow |
| SMILES | O=C(OC/C=C(C)/CC/C=C(C)/CC/C=C(C)/C)CC1=C(C)N(C(C2=CC=C(Cl)C=C2)=O)C3=C1C=C(OC)C=C3 |
| Signaling Pathway | Immunology/Inflammation; Autophagy |
| Storage | Pure form: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 6 months; -20°C, 1 month. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
Indometacin farnesil (IMF) is a newly synthesized prodrug of indomethacin, made by esterifying the carboxyl group of indomethacin with farnesol to reduce the occurrence of side-effects. The modification is intended to lower hepatic extraction and subsequent rapid metabolism of the drug so that lymphatic absorption becomes a major route, and it was also anticipated that hydrolytic enzymes in plasma and tissues, including inflamed tissue, would effectively release indomethacin from IMF[2].
In Vivo
Local administration of Indomethacin farnesil (IMF) can effectively release indomethacin[1].
| Animal Model | Rats[1]. |
|---|---|
| Dosage | 50 nmol a rat paw. |
| Administration | Once. |
| Result | Reduced the level of PGE2 in a dose dependent manner. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
